Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
16 July 2021 - 6:05AM
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical
company advancing new treatments for patients suffering from
serious diseases but underserved by today’s therapies, today
announced the appointment of Jennifer Moses, CPA to the Company’s
Board of Directors and as Chair of the Audit Committee.
“We are excited to welcome Jennifer to our Board of Directors
and as Chair of the Audit Committee. She provides strong financial
and strategic experience as a successful leader in the
biotechnology industry. Her addition to the Board and as Chair of
the Audit Committee will be of great benefit to Viridian as we
rapidly advance the clinical development of VRDN-001 and VRDN-002,"
commented Jonathan Violin, Ph.D., President and Chief Executive
Officer of Viridian.
"Viridian has successfully assembled an accomplished management
team and raised significant capital over the past few quarters to
advance the development of multiple product candidates designed to
create meaningful new options for patients suffering from Thyroid
Eye Disease. It is an honor to join the Company’s Board and support
this management team in bringing value to patients and
stockholders," said Moses.
Ms. Moses brings extensive experience as a financial executive
working with life sciences and biotechnology companies. Currently,
Ms. Moses serves as chief financial officer at G1 Therapeutics,
Inc. (Nasdaq: GTHX), a commercial-stage oncology company, where she
has been a leader within the Finance team since 2015. During this
time, she has provided strategic financial counsel on G1’s IPO and
subsequent financings, spearheaded the implementation of financial
controls and systems, and overseen the expansion of the finance
department. Previously, Ms. Moses was a partner at Rankin McKenzie,
LLC, where she served as acting chief financial officer and
controller for venture-backed companies. In addition to preparing
clients for growth by developing long-term financial plans and
implementing financial systems, reporting and analysis, she led
multiple clients through private placement offerings and
acquisitions. Before joining Rankin McKenzie, Ms. Moses held roles
of increasing responsibility at Deloitte, including providing tax
services to clients and later focusing on strategic planning and
internal communications in the Office of the CEO of Deloitte Tax.
Ms. Moses received her B.S. in Accounting from The Pennsylvania
State University and is a certified public accountant in the State
of North Carolina.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new
treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is an anti-IGF-1R monoclonal antibody in development for
TED, a debilitating auto-immune disease that causes inflammation
and fibrosis within the orbit of the eye which can cause double
vision, pain, and potential blindness. Patients with severe disease
often require multiple remedial surgeries to the orbit, eye
muscles, and eyelids. Viridian is based in Boulder, Colorado, and
Waltham, Massachusetts. Learn more about Viridian and its programs
at https://www.viridiantherapeutics.com/.
Follow us on Twitter @ViridianThera and on LinkedIn.
Viridian
Contacts:Investors:Dan FerryLifeSci
Advisors617-430-7576IR@viridiantherapeutics.com
Media:Darby PearsonVerge Scientific
Communications703-587-0831PR@viridiantherapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Sep 2024 to Oct 2024
G1 Therapeutics (NASDAQ:GTHX)
Historical Stock Chart
From Oct 2023 to Oct 2024